Maridebart cafraglutide clinical trials
Also written AMG 133.
How each study uses maridebart cafraglutide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the maridebart cafraglutide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
32 studies that test it; most in 2025 (14)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 5 |
| 2025 | 14 |
| 2026 | 10 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 32 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 11, 6 in phase 3
Studies that test maridebart cafraglutide, phase 3 first.
- Jan 2027Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightPhase 3 · Amgen
- Jan 2027Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightPhase 3 · Amgen
- Apr 2027Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity DiseasePhase 3 · Amgen
- Jun 2027Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or OverweightPhase 3 · Amgen
- Aug 2027Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure TherapyPhase 3 · Amgen
- Aug 2027Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) TherapyPhase 3 · Amgen
- Nov 2026A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes MellitusPhase 1 · Amgen
- Nov 2026Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or ObesityPhase 1 · Amgen
- Mar 2027Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Available in the Body After a Single Subcutaneous DosePhase 1 · Amgen
- Jul 2027Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple DosesPhase 1 · Amgen
Studies
Open first, then newest update. How each study uses maridebart cafraglutide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 32
- Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)RecruitingPhase 3AmgenNCT07575399Written as Maridebart Cafraglutide
- Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or OverweightRecruitingPhase 3AmgenNCT07871409Written as Maridebart cafraglutide
- Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple DosesNot yet recruitingPhase 1AmgenNCT07921316Written as Maridebart cafraglutide
- Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 DiabetesRecruitingPhase 3AmgenNCT07866066Written as Maridebart cafraglutide
- Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)RecruitingPhase 1AmgenNCT07908316Written as Maridebart cafraglutide
- Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityRecruitingPhase 3AmgenNCT07037459Written as Maridebart cafraglutide
- Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)RecruitingPhase 3AmgenNCT07684235Written as Maridebart cafraglutide
- Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)RecruitingPhase 3AmgenNCT07684144Written as Maridebart Cafraglutide
- Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Available in the Body After a Single Subcutaneous DoseNot yet recruitingPhase 1AmgenNCT07832799Written as Maridebart Cafraglutide
- Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityActive, not recruitingPhase 3AmgenNCT07037433Written as Maridebart Cafraglutide
- A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or ObesityCompletedPhase 1AmgenNCT07310563Written as AMG 133
- Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure TherapyActive, not recruitingPhase 3AmgenNCT07225686Written as Maridebart cafraglutide
- Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) TherapyActive, not recruitingPhase 3AmgenNCT07226765Written as Maridebart cafraglutide
- A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or OverweightActive, not recruitingPhase 2AmgenNCT07441252Written as Maridebart cafraglutide
- Effect of Maridebart Cafraglutide on the Heart's Electrical ActivityCompletedPhase 1AmgenNCT07229157Written as Maridebart Cafraglutide
- Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightActive, not recruitingPhase 3AmgenNCT06858839Written as Maridebart Cafraglutide
- A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)Active, not recruitingPhase 2AmgenNCT06660173Written as Maridebart Cafraglutide
- A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous PresentationsCompletedPhase 1AmgenNCT07313761Written as Maridebart Cafraglutide
- A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or ObesityCompletedPhase 1AmgenNCT07717814Written as AMG 133 (frozen liquid)
- Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or ObesityActive, not recruitingPhase 1AmgenNCT07523711Written as Maridebart Cafraglutide
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting2
Newly registered2
- Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple DosesNov 6, 2026NCT07921316
- Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)Nov 2, 2026NCT07908316
Codes
What other systems call maridebart cafraglutide · ClinicalTrials.gg INT018641
- UNII (FDA) Z24U3U73HNMARIDEBART CAFRAGLUTIDEOne source FDA
- NCI Thesaurus C199209Maridebart CafraglutideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | Z24U3U73HN | MARIDEBART CAFRAGLUTIDE | One source FDA |
| NCI Thesaurus | C199209 | Maridebart Cafraglutide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.